Infections caused by cytomegalovirus, particularly those that erupt during immunosuppression, have been a particular bugbear of transplant patients, but a new generation of anti-CMV agents are nearing the market, with Merck & Co. Inc.’s letermovir forging ahead in the latter stages of the race to market.
New Anti-CMV Therapies Post-Transplant: Merck & Co Leads The Pack
Merck & Co’s investigational anti-CMV therapy letermovir is expected to be filed for approval later this year and could be the first of a new generation of anti-CMV therapies, following top-line Phase III data showing it reduced all-cause mortality in bone marrow transplant patients.

More from Clinical Trials
More from R&D
• By
On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.
• By
The not-for-profit’s senior vice president Martin Ridderstråle explains how it is expanding grants for basic research to improve "human and planetary" health.
• By
As the PDUFA date for the UK major’s IL-5 inhibitor draws close.